Profil
Kristie Wagner worked as Vice President & Controller at Akebia Therapeutics, Inc. from 2013 to 2021, and then as Vice President & Controller at Entasis Therapeutics Holdings, Inc. in 2021-2022.
She holds a Master's in Business Administration from Suffolk University and an undergraduate degree from Massachusetts College of Liberal Arts.
Anciens postes connus de Kristie Wagner
| Sociétés | Poste | Fin |
|---|---|---|
| AKEBIA THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 01/02/2021 |
| ENTASIS THERAPEUTICS HOLDINGS INC. | Director of Finance/CFO | - |
Formation de Kristie Wagner
| Suffolk University | Masters Business Admin |
| Massachusetts College of Liberal Arts | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| AKEBIA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Entasis Therapeutics Holdings, Inc.
 Entasis Therapeutics Holdings, Inc. BiotechnologyHealth Technology Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. | Health Technology |
